Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New option for chronic graft vs. host

Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.

Key clinical point: The ROCK2-selective inhibitor KD025 shows encouraging activity in cGVHD.

Major finding: Clinical response rates in cohorts 1 and 2 were 65% and 69%, respectively.

Study details: Preliminary findings in 33 patients from a phase 2a trial.

Disclosures: The trial is sponsored by Kadmon. Dr. Lazaryan reported advisory board membership and consultancy for GLyPharma Therapeutic.

Source: Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.

Read the article.

Citation:

Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.